HIMS
VENTE TOTALE: 16 773 titres (~467 128,05 $ US)
- Insiders
- Autor Deborah M.
- Total bought
- —
- Total sold
- $467,128
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-06
HIMS presents a mixed fundamental picture with improving profitability but rising leverage and thin margins, offset almost entirely by a severely negative catalyst environment driven by multiple securities law…
The first sentence of the analysis written for HIMS on 2026-09-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 73.8% | 79.5% | 82.0% | 77.6% | 75.2% | |
| Ebit Margin | 5.3% | 4.9% | -2.5% | -12.5% | -40.8% | |
| Ebitda Margin | 7.6% | 6.0% | -1.4% | -11.1% | -39.3% | |
| Operating Profit Margin | 4.5% | 4.2% | -3.4% | -13.0% | -42.3% | |
| Pretax Profit Margin | 5.3% | 4.9% | -2.5% | -12.5% | -40.8% | |
| Continuous Operations Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Net Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Bottom Line Profit Margin | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | |
| Current Ratio | 1.898 | 1.788 | 2.996 | 4.518 | 3.407 | |
| Quick Ratio | 1.612 | 1.497 | 2.742 | 4.068 | 3.236 | |
| Solvency Ratio | 0.113 | 0.620 | -0.144 | -1.066 | -1.205 | |
| Cash Ratio | 0.565 | 0.996 | 1.093 | 0.976 | 0.906 | |
| Price To Earnings Ratio | 56.965 | 41.690 | -80.909 | -20.031 | -11.293 | |
| Price To Earnings Growth Ratio | -33.040 | -0.066 | 1.233 | 0.447 | -0.823 | |
| Forward Price To Earnings Growth Ratio | -33.040 | -0.066 | 1.233 | 0.447 | -0.823 | |
| Price To Earnings Diluted Ratio | 63.667 | 45.623 | -80.909 | -20.031 | -11.293 | |
| Price To Earnings Diluted Growth Ratio | -16.872 | -0.078 | 1.233 | 0.447 | -0.823 | |
| Price To Book Ratio | 13.504 | 10.953 | 5.416 | 4.205 | 3.656 | |
| Price To Sales Ratio | 3.111 | 3.536 | 2.137 | 2.488 | 4.500 | |
| Price To Free Cash Flow Ratio | 98.761 | 26.326 | 39.649 | -38.811 | -31.036 | |
| Price To Operating Cash Flow Ratio | 24.348 | 20.795 | 25.355 | -49.412 | -35.552 | |
| Debt To Assets Ratio | 0.520 | 0.016 | 0.023 | 0.014 | 0.013 | |
| Debt To Equity Ratio | 2.072 | 0.024 | 0.029 | 0.017 | 0.016 | |
| Debt To Capital Ratio | 0.674 | 0.023 | 0.028 | 0.017 | 0.016 | |
| Long Term Debt To Capital Ratio | 0.643 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 3.983 | 1.484 | 1.282 | 1.175 | 1.257 | |
| Working Capital Turnover Ratio | 8.733 | 8.412 | 5.052 | 2.933 | 1.885 | |
| Operating Cash Flow Ratio | 0.742 | 1.134 | 0.831 | -0.553 | -0.434 | |
| Operating Cash Flow Sales Ratio | 0.128 | 0.170 | 0.084 | -0.050 | -0.127 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.247 | 0.790 | 0.639 | 1.273 | 1.146 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.268 | 22.132 | 7.387 | -4.999 | -6.277 | |
| Capital Expenditure Coverage Ratio | 1.327 | 4.760 | 2.774 | -3.661 | -6.873 | |
| Dividend Paid And Capex Coverage Ratio | 1.327 | 4.760 | 2.774 | -3.661 | -6.873 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 45.937 | 56.444 | -147.350 | -21.799 | -10.843 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 73.8% | ▼-5.6% | ▼-3.8% |
| Ebit Margin | 5.3% | ▲0.4% | ▲14.4% |
| Ebitda Margin | 7.6% | ▲1.6% | ▲15.2% |
| Operating Profit Margin | 4.5% | ▲0.3% | ▲14.5% |
| Pretax Profit Margin | 5.3% | ▲0.4% | ▲14.4% |
| Continuous Operations Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Net Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Bottom Line Profit Margin | 5.5% | ▼-3.1% | ▲13.6% |
| Current Ratio | 1.898 | ▲0.110 | ▼-1.023 |
| Quick Ratio | 1.612 | ▲0.115 | ▼-1.019 |
| Solvency Ratio | 0.113 | ▼-0.507 | ▲0.450 |
| Cash Ratio | 0.565 | ▼-0.431 | ▼-0.342 |
| Price To Earnings Ratio | 56.965 | ▲15.275 | ▲59.681 |
| Price To Earnings Growth Ratio | -33.040 | ▼-32.973 | ▼-26.590 |
| Forward Price To Earnings Growth Ratio | -33.040 | ▼-32.973 | ▼-26.590 |
| Price To Earnings Diluted Ratio | 63.667 | ▲18.044 | ▲64.255 |
| Price To Earnings Diluted Growth Ratio | -16.872 | ▼-16.793 | ▼-13.653 |
| Price To Book Ratio | 13.504 | ▲2.551 | ▲5.957 |
| Price To Sales Ratio | 3.111 | ▼-0.425 | ▼-0.043 |
| Price To Free Cash Flow Ratio | 98.760 | ▲72.434 | ▲79.783 |
| Price To Operating Cash Flow Ratio | 24.348 | ▲3.552 | ▲27.241 |
| Debt To Assets Ratio | 0.520 | ▲0.504 | ▲0.403 |
| Debt To Equity Ratio | 2.072 | ▲2.048 | ▲1.640 |
| Debt To Capital Ratio | 0.674 | ▲0.651 | ▲0.523 |
| Long Term Debt To Capital Ratio | 0.643 | ▲0.643 | ▲0.514 |
| Financial Leverage Ratio | 3.983 | ▲2.499 | ▲2.147 |
| Working Capital Turnover Ratio | 8.733 | ▲0.321 | ▲3.330 |
| Operating Cash Flow Ratio | 0.742 | ▼-0.392 | ▲0.398 |
| Operating Cash Flow Sales Ratio | 0.128 | ▼-0.042 | ▲0.087 |
| Free Cash Flow Operating Cash Flow Ratio | 0.246 | ▼-0.543 | ▼-0.572 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.268 | ▼-21.864 | ▼-3.434 |
| Capital Expenditure Coverage Ratio | 1.327 | ▼-3.433 | ▲1.662 |
| Dividend Paid And Capex Coverage Ratio | 1.327 | ▼-3.433 | ▲1.662 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 45.937 | ▼-10.507 | ▲61.459 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.30B | $5.22B | $1.86B | $1.31B | $1.22B | |
| Enterprise value | $8.20B | $5.01B | $1.78B | $1.27B | $1.16B | |
| EV / Sales | 3.49x | 3.40x | 2.04x | 2.41x | 4.26x | |
| EV / Op. cash flow | 27.32x | 19.96x | 24.18x | -47.85x | -33.62x | |
| EV / Free cash flow | 110.82x | 25.27x | 37.80x | -37.58x | -29.35x | |
| EV / EBITDA | 45.94x | 56.44x | -147.35x | -21.80x | -10.84x | |
| Net debt / EBITDA | 5.00x | -2.36x | 7.19x | 0.71x | 0.62x | |
| Current ratio | 1.90x | 1.79x | 3.00x | 4.52x | 3.41x | |
| Income quality | 2.34x | 1.99x | -3.12x | 0.40x | 0.32x | |
| Graham number | $6 | $5 | — | — | — | |
| Graham net-net | -$4 | $0 | $1 | $1 | $1 | |
| Tax burden | 103.6% | 175.8% | 109.2% | 100.0% | 97.2% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $363.2M | $174.5M | $176.6M | $168.7M | $190.7M | |
| Invested capital | $1.29B | $423.6M | $351.8M | $317.5M | $332.6M | |
| Return on assets | 6.0% | 17.8% | -5.3% | -17.9% | -25.6% | |
| Operating ROA | 7.4% | 10.8% | -7.3% | -17.5% | -42.7% | |
| Return on tangible assets | 7.6% | 22.9% | -7.6% | -28.1% | -37.9% | |
| Return on equity | 23.7% | 26.4% | -6.8% | -21.1% | -32.2% | |
| Return on invested capital | 6.0% | 12.7% | -8.3% | -21.5% | -32.6% | |
| Return on capital employed | 6.0% | 12.7% | -8.4% | -21.6% | -33.7% | |
| Earnings yield | 1.8% | 2.4% | -1.3% | -5.0% | -8.8% | |
| Free cash flow yield | 1.0% | 3.8% | 2.5% | -2.6% | -3.2% | |
| Capex / Op. cash flow | 75.3% | 21.0% | 36.1% | -27.3% | -14.6% | |
| Capex / Depreciation | 414.7% | 308.7% | 278.4% | 97.0% | 122.9% | |
| Capex / Sales | 9.6% | 3.6% | 3.0% | 1.4% | 1.8% | |
| SG&A / Sales | 50.8% | 57.3% | 66.1% | 70.4% | 91.8% | |
| R&D / Sales | 6.4% | 5.3% | 5.5% | 5.5% | 8.2% | |
| Stock comp / Sales | 5.8% | 6.3% | 7.6% | 8.1% | 24.7% | |
| Intangibles / Total assets | 22.0% | 22.1% | 29.3% | 36.2% | 32.5% | |
| Days sales outstanding | 5d | 2d | 3d | 2d | 5d | |
| Days payables outstanding | 85d | 110d | 100d | 100d | 106d | |
| Operating cycle | 74d | 79d | 55d | 69d | 78d | |
| Cash conversion cycle | -11d | -31d | -45d | -31d | -28d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+39.9%EV / Sales ▲+2.9%EV / EBITDA ▼-18.6%EV / Op. cash flow ▲+7.359Earnings yield ▼-0.007Graham number ▲+0.172
Profitability
Return on equity ▼-0.027Return on assets ▼-0.119Return on invested capital ▼-0.067Return on capital employed ▼-0.067Operating ROA ▼-0.034Income quality ▲+0.345Tax burden ▼-0.722
Efficiency
Days sales outstanding ▲+3.495Days payables outstanding ▼-24.563Operating cycle ▼-5.247Cash conversion cycle ▲+19.315Capex / Sales ▲+0.061R&D / Sales ▲+0.010
Balance-sheet strength
Current ratio ▲+0.110Net debt / EBITDA ▲+7.355Working capital ▲+188743000.000Invested capital ▲+863058000.000Intangibles / Total assets -0.000
Change over 5 years
Valuation
Market cap ▲+497.1%EV / Sales ▼-18.0%EV / EBITDA ▲+523.7%EV / Op. cash flow ▲+60.946Earnings yield ▲+0.106
Profitability
Return on equity ▲+0.559Return on assets ▲+0.316Return on invested capital ▲+0.386Return on capital employed ▲+0.397Operating ROA ▲+0.500Income quality ▲+2.017Tax burden ▲+0.064
Efficiency
Days sales outstanding ▲+0.196Days payables outstanding ▼-21.247Operating cycle ▼-4.473Cash conversion cycle ▲+16.774Capex / Sales ▲+0.078R&D / Sales ▼-0.019
Balance-sheet strength
Current ratio ▼-1.509Net debt / EBITDA ▲+4.378Working capital ▲+172523000.000Invested capital ▲+954058000.000Intangibles / Total assets ▼-0.105
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-21 Kaplan Fox & Kilsheimer LLP Alerts Investors of Hims & Hers Health, Inc. (HIMS) to an Investigation of Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
- 2026-08-21 HIMS INVESTIGATION: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm RADNOR, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Hims & Hers Health, Inc. (NYSE: HIMS) on behalf of investors who purchased or acquired Hims & Hers Health, Inc. securities and experienced significant financial losses.
- 2026-08-21 Bragar Eagel & Squire, P.C. is Investigating Hims & Hers Health, Inc. on Behalf of Hims & Hers Stockholders and Encourages Investors to Contact the Firm Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS) To Contact Him Directly To Discuss Their Options
- 2026-08-21 HIMS Stock More Than Doubled in 6 Months: What''s Driving the Rally? Hims & Hers'' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.
- 2026-08-19 Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) on Behalf of Investors for Potential Securities Law Violations New York, New York--(Newsfile Corp. - August 19, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Hims & Hers investor and have suffered losses, or if you have information that could assist in the Hims & Hers investigation, you may CLICK HERE to contact us.
- 2026-08-19 Hims & Hers Rejects Privacy Allegations While Promising Expanded Patient Access Hims & Hers Health Inc. (NYSE:HIMS) CEO Andrew Dudum defended the telehealth company as it navigates a U.S. Federal Trade Commission lawsuit concerning data privacy and advertising practices.
- 2026-08-19 Hims & Hers: Buying The Margin Dip Hims & Hers Health (HIMS) is rated a buy at current levels, driven by robust international expansion and product innovation. International revenue surged over 17-fold YoY to $131M, with Eucalyptus acquisition and new markets fueling growth and future $600M+ 2026 target. AI investment aims to reduce customer-support costs and improve retention, with payback expected in 12–18 months as in-house capabilities scale.
- 2026-08-19 Berger Montague PC Investigates Hims & Hers Health, Inc.''s Board of Directors for Breach of Fiduciary Duty (HIMS) Philadelphia, Pennsylvania--(Newsfile Corp. - August 19, 2026) - National plaintiffs'' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made subscription cancellations unnecessarily difficult.
- 2026-08-19 Hims & Hers'' Chief Accounting Officer Is Leaving. Here''s What Her Latest Insider Filing Shows The disposition involved 6,490 shares worth about $183,000 at a price of $28.15 per share on August 14. All shares were withheld by the issuer to cover tax obligations following the quarterly vesting of restricted stock units (RSUs).
- 2026-08-19 An Insider at Hims & Hers Just Filed. Here''s What It Says About Buying the Dip The disposition involved 21,500 shares valued at about $605,000 as of the August 14 transaction date. Soleil Boughton maintains direct ownership of 339,000 shares and holds additional derivative securities following the liquidation.